Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRx Pharmaceuticals Inc (NRXPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: NRXPW (1-star) is a SELL. SELL since 1 days. Profits (-10.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.21% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 714.61M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.55 | 52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 |
52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13364027 |
Shares Outstanding - | Shares Floating 13364027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NRx Pharmaceuticals Inc
Company Overview
History and Background
NRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of central nervous system disorders, primarily those associated with suicidal ideation, chronic pain, and PTSD. Founded to address unmet medical needs, the company has evolved through research, clinical trials, and strategic partnerships.
Core Business Areas
- Suicidal Depression: Developing NRX-101, a ketamine-based therapeutic, and other treatments for severe bipolar depression with acute suicidal ideation and behavior.
- Chronic Pain: Researching and developing non-opioid treatments for chronic pain conditions.
- PTSD: Developing treatments for Post Traumatic Stress Disorder
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company structure is typical of a biopharmaceutical company, with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- NRX-101: An investigational oral formulation of D-cycloserine designed to stabilize the antidepressant effects of ketamine and other treatments in patients with severe bipolar depression and acute suicidal ideation. Market share is currently 0 as it is still in development. Key competitors include pharmaceutical companies developing alternative treatments for depression, such as Janssen (SPRAVATO).
- NRX-100 (IV Ketamine): Intravenous ketamine formulation, used as an initial treatment to stabilize patients. Market share is not directly measurable, as ketamine is used off-label for depression; it faces competition from Janssen's SPRAVATO and generic ketamine providers.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The market for mental health treatments is substantial and growing, driven by increasing awareness and diagnosis of mental health conditions.
Positioning
NRx Pharmaceuticals is positioned as an innovator in the treatment of severe mental health disorders, particularly suicidal depression, using novel combinations of existing medications and new therapeutic approaches.
Total Addressable Market (TAM)
The estimated TAM for depression and suicidal ideation is substantial, potentially exceeding $10 billion annually. NRx Pharmaceuticals aims to capture a segment of this market with its innovative treatments.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Focus on unmet medical needs
- Experienced leadership team
- Proprietary intellectual property
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small market capitalization
- High dependence on key product candidates.
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Increased awareness of mental health issues
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Generic competition for existing medications
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- JNJ
- TEVA
- MYL
Competitive Landscape
NRx Pharmaceuticals faces significant competition from established pharmaceutical companies with greater resources. Its advantage lies in its novel therapeutic approaches and focus on unmet medical needs.
Major Acquisitions
TherapeuticsMD
- Year: 2023
- Acquisition Price (USD millions): 10
- Strategic Rationale: Acquire FDA-approved capabilities in hormone therapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by investment in R&D and clinical trials. Revenue growth is minimal.
Future Projections: Future growth depends heavily on the successful development and commercialization of its drug candidates. Analyst projections vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for NRX-101 and efforts to secure funding and partnerships.
Summary
NRx Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on developing treatments for severe mental health disorders. While it has innovative therapeutic approaches, it faces significant challenges, including limited financial resources and the need for successful clinical trial outcomes. The company needs to secure additional funding and demonstrate clinical efficacy to achieve its growth potential. It is working on niche areas of unmet needs. Its success is dependent on its pipeline and will live and die by it.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-01 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.